Feed SRRK
SR

Scholar Rock

SRRK · NASDAQ

$49.37 -1.28% (-$0.64)
1M -9.78%
Market Cap $5.92B
P/E Ratio -
Div. Yield -
ROE 160.19%

Bulios Fair Price

$44.76

9.3% downside

Current Price

$49.37

Undervalued Fair Value Overvalued

According to Bulios Fair Price, SRRK is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/B 23.31x
P/E N/A
P/FFO N/A
Growth
15 /100
Declining
Book val. growth 1.93%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor
ROIC 88.80%
Asset turnover 0.00x
ROE 160.19%
Debt
52 /100
Moderate
Debt/Equity 0.80x
Int. coverage -37.23x
Current ratio 7.02x
Stability
71 /100
Stable
Beta 0.68x
Profitable years 0
EPS volatility 22.75%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about SRRK
Online

About the company

Scholar Rock Holding Corporation is a U.S.-based biotechnology company focused on developing therapeutics that specialize in innovative approaches to modulating biological signaling pathways. The company concentrates on developing drugs that target proteins and signaling molecules involved in cell growth and development, particularly in the fields of neurology, oncology, and immunology. Scholar Rock is positioned as a leader in highly targeted therapies with the potential to transform the treatment of a range of serious and previously difficult-to-treat diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

David L. Hallal

Employees

289

Headquarters

Cambridge

Upcoming events

13 NOV

Earnings

Upcoming earnings report

57d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.